Journal article
The New Dyslipidemia Guidelines: What Is the Debate?
Abstract
Dyslipidemia is a major risk factor for the development of atherosclerotic disease. Therefore, lifestyle interventions and pharmacological approaches to decrease cholesterol are widely used in cardiovascular disease prevention. The introduction and widespread use of 3-hydroxy-3 methylglutaryl coenzyme A inhibitors (statins) for individuals at risk of atherosclerotic disease has been an important advance in cardiovascular care. There can be no …
Authors
Anderson TJ; Mancini GBJ; Genest J; Grégoire J; Lonn EM; Hegele RA
Journal
Canadian Journal of Cardiology, Vol. 31, No. 5, pp. 605–612
Publisher
Elsevier
Publication Date
5 2015
DOI
10.1016/j.cjca.2014.11.007
ISSN
0828-282X